Importance of early characterization of physicochemical properties in developing high-dose intravenous infusion regimens for poorly water-soluble compounds

PDA Journal of Pharmaceutical Science and Technology

Volumn 64, Issue 6, 2010, Pages 517-526

  Jain, Akash ^a   Zheng, Weijia ^a,b   Garad, Sudhakar ^a   Weaver, Margaret ^a   Panicucci, Riccardo ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Formulation; Infusion; Intravenous; Physicochemical properties; Precipitation

Indexed keywords

CHEMICAL COMPOUND; WATER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; RAT; SOLUTION AND SOLUBILITY; ANIMAL; CHEMISTRY; MEDICINAL CHEMISTRY; SOLUBILITY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; PHYSICOCHEMICAL PHENOMENA; SOLUBILITY; WATER;

EID: 83755178452     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Lee, Y. C.; Zocharski, P. D.; Samas, B. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 2003, 253 (1-2), 111-119. (Pubitemid 36197836)
2. Lipinski, C. A. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5 (3), 82.
3. Sweetana, S.; Akers, M. J. Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 1996, 50 (5), 330-342. (Pubitemid 26392756)
4. Nema, S.; Washkuhn, R. J.; Brendel, R. J. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51 (4), 166-171. (Pubitemid 28123757)
5. Powell, M. F.; Nguyen, T.; Baloian, L. Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52 (5), 238-311.
6. Strickley, R. G. Parenteral formulations of small molecule therapeutics marketed in the United States (1999). Part III. PDA J. Pharm. Sci. Technol. 2000, 54 (2), 152-169. (Pubitemid 30321145)
7. Strickley, R. G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21 (2), 201-230. (Pubitemid 38221966)
8. Wong, J.; Brugger, A.; Khare, A.; Chaubal, M.; Papadopoulos, P.; Rabinow, B.; Kipp, J.; Ning, J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Del. Rev. 2008, 60 (8), 939-954.
9. Stahl, P. H.; Wermuth, C. G. Handbook of Pharmaceutical Salts, Properties, Selection and Use; Verlag Helvetica Chimica Acta: Zürich, 2002; p 334.
10. Yalkowsky, S. H. Solubilization by Complexation, Solubility and Solubilization in Aqueous Media; Oxford University Press: New York, 1999; p 316.
11. Yalkowsky, S. H.; Krzyzaniak, J. F.; Ward, G. H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87 (7), 787-796. (Pubitemid 28319406)
12. Bittner, B.; Mountfield, R. J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Devel. 2002, 5 (1), 59-71. (Pubitemid 34453243)
13. Kwan, Y. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists; Kluwer Academic Publishers: New York, 2002; p 229.
14. Stella, V. J.; He, Q. Cyclodextrins. Toxicol. Pathol. 2008, 36 (1), 30-42.